

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, 16/18, A61K 38/17, C12N 15/11, C12Q 1/68, G01N 33/50		A1	(11) International Publication Number: WO 98/39444 (43) International Publication Date: 11 September 1998 (11.09.98)
(21) International Application Number: PCT/US98/04402		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 5 March 1998 (05.03.98)			
(30) Priority Data: 08/812,828 6 March 1997 (06.03.97) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/812,828 (CIP) Filed on 6 March 1997 (06.03.97)			
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US).			
(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(54) Title: PROTEIN KINASE C INHIBITOR-LIKE PROTEIN (IPKC-2)			
(57) Abstract			
<p>The present invention provides a human protein kinase C inhibitor-like protein (IPKC-2) and polynucleotides which identify and encode IPKC-2. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention provides methods for treating diseases associated with expression of IPKC-2.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROTEIN KINASE C INHIBITOR-LIKE PROTEIN (IPKC-2)

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of a novel protein kinase C inhibitor-like protein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer, autoimmune disorders, and cognitive disorders.

BACKGROUND ART

Protein kinase C, PKC, belongs to a family of widely distributed signal transduction proteins important for cell growth, differentiation, and other responses. PKC is activated by growth factors, hormones, and other external messengers via stimulation of phospholipase C and is responsible for the generation of the second messengers, inositol triphosphate and diacylglycerol. All members of the PKC family share significant sequence homology and perform signal transduction via protein phosphorylation. Almost all cell types express one or more isoforms of PKC.

The activity of an endogenous inhibitor of PKC has been detected in bovine, avian, murine, and human tissues. The first complete primary structure of an endogenous inhibitor of protein kinase C, PKCI-1, was derived from bovine brain (Pearson, J.D. et al. (1990) *J. Biol. Chem.* 265: 4583-4591). PKCI-1 has a specific site of interaction with PKC and inhibits the ability of PKC to carry out phosphorylation. In addition to the bovine sequence, a complete amino acid sequence of PKCI-1 has been deduced from the maize, rat, and human genes (Simpson G.G. et al. (1994) *Biochim. Biophys. Acta.* 1222: 306-308; Waller S.J. and Murphy D. (1994, GI 493051 and Brzoska P.M. et al. (1995) *Proc. Natl. Acad. Sci.* 92: 7824-7828). The bovine PKCI-1 was shown to be a zinc (Zn) binding protein (Simpson et al., *supra*). The site of Zn binding has been localized to a 11 amino acid fragment (Mozier et al. (1991) *FEBS Lett.* 279:14-18), and the Zn binding domain is conserved among PKCI-1 molecules.

PKC activation plays a significant role in multidrug resistance (MDR), a major contributing factor in the failure of many chemotherapeutic cancer regimens (Grunicke H. et al. (1994) *Ann. Hematol.* 69:S1-6). PKC regulates proteins, such as FOS, Jun, glutathione S-transferase, deoxy-thymidine monophosphate synthase, metallothionein, and mdr-1-encoded P-glycoprotein, that act to make cancer cells drug resistant. This regulation works through phosphorylation and results in increased transcription of the genes encoding these proteins.

Conversely, PKC inhibitors or antagonists interfere with the phosphorylation function of PKC which reduces the expression of genes that mediate MDR. In addition to its role in MDR, PKC activation is often a critical event in tumor promotion (O'Brian C.A. and Ward N.E. (1989)

Cancer Metastasis Rev. 8:199-214; O'Brian C.A. et al. (1995) Prog. Clin. Biol. Res. 391:117-120). For example, PKC alpha phosphorylates and activates the growth promoting gene Raf-1 (Kolch W. et al. (1993) Nature 364:249-252). Without PKC induced Raf-1 activation, the ability to transform NIH3T3 cells is greatly inhibited. In cultured melanocytes loss of a particular PKC 5 isotype has been implicated in cellular transformation (Yamanishi D.T. et al. (1994) Crit. Rev. Oncog. 5:429-450). Thus, PKC inhibitors (PKCI) are promising agents for cancer treatment.

PKC participates in the sequence of molecular events that underlie learning and memory (Olds J.L. and Alkon D.L. (1991) New Biol. 3:27-35). The cellular distribution of PKCs changes as a result of memory storage in cells that have been demonstrated to act in memory and learning 10 (Saito N. et al. (1994) Brain Res. 656:245-256). PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning, further implicating PKCs in learning and memory (Abeliovich A. et al. (1993) Cell 75:1263-1271). Memory deterioration is one of the main characteristics and earliest signs of Alzheimer's disease.

PKCs can act in several ways to stimulate apoptosis (programmed cell death) in various 15 cell types. PKCs can block the activation of other calcium-dependent enzymes triggering apoptosis (Lucas M. et al. (1995) Gen. Pharmacol. 26:881-887). Activation of phosphatases by ceramide and inhibition of PKC by sphingosine mediates the sphingomyelin pathway to apoptosis. A putative PKC target, p34cdc2, can act to stimulate apoptosis when its activity is uncoupled from the completion of DNA replication. In addition, p21Ras mediates proliferative 20 responses and also renders cells susceptible to apoptosis after inhibition of PKC activity (Chen C.Y. et al. (1996) J. Biol. Chem. 271:2376-2379). The T lymphocytes of mice in which the Fas mediated apoptosis pathway has been knocked out rely on a PKC dependent apoptotic mechanism for selection against self-reactive T-cells (Ohkusu K. et al. (1995) Eur. J. Immunol. 25:3180-3186). Thus, PKC has a role in immune cell development. Saikosponin b2 induces 25 apoptosis in B16 melanoma cells by down regulation of PKC activity (Zong et al. (1996) Biochem. Biophys. Res. Commun. 219:480-485). Furthermore, proteolytic activation of PKC delta by an ICE-like protease stimulates apoptosis in human tumor cell line U-937 (Emoto Y. et al. (1995) EMBO J. 14:6148-5156).

There is much evidence to suggest that PKC inhibitors may modify PKC activity in 30 normal or disease cells. For example, PKC inhibitors have been shown to inhibit the growth of cancer cells both in vitro and in vivo (Levitzki A. (1994) Eur. J. Biochem. 226:1-13). The synthetic PKC inhibitor bisindolylmaleimide GF109203X (bisi) can affect the neuroblastoma cell line Neuro-2A in one of two ways. Without serum, neurite outgrowth is potentiated by bisi,

while with serum, apoptosis occurs (Behrens M.M. et al. Cell Growth Differ. (1995) 6: 1375-1380). Other PKC inhibitors including hypericin, staurosporine, tamoxifen, and the phorbol ester PMA induce apoptosis in the human neuroblastoma cell line SK-N-SH (Zhang W. et al. (1995) Cancer Lett. 96:31-35). PKC inhibitors may have utility beyond cancer indications.

5 The PKC inhibitor H-7 induces apoptosis in Fas minus mouse T lymphocytes (Ohkusu et al. (1995) *supra*).

Discovery of proteins related to human protein kinase C inhibitor-like proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions useful in diagnosis, prevention, and treatment of cancer, autoimmune disorders, and cognitive disorders.

10

DISCLOSURE OF THE INVENTION

The present invention features a novel human protein kinase C inhibitor-like protein hereinafter designated IPKC-2 and characterized as having similarity to rat putative protein kinase C inhibitor, human PKCI-1, and bovine putative protein kinase C inhibitor.

Accordingly, the invention features a substantially purified IPKC-2 having the amino acid sequence shown in SEQ ID NO:1.

One aspect of the invention features isolated and substantially purified polynucleotides that encode IPKC-2. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.

The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode IPKC-2.

25 The present invention also features antibodies which bind specifically to IPKC-2, and pharmaceutical compositions comprising substantially purified IPKC-2. The invention also features agonists and antagonists of IPKC-2 and the use thereof for treating cancer, autoimmune disorders, and cognitive disorders. The invention also features a method for producing IPKC-2, and methods for treating cancer, autoimmune disorders, and cognitive disorders by administering

30 IPKC-2 or an IPKC-2 fragment or derivative thereof.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of IPKC-2. The alignment was produced using MacDNASIS PRO™.

software (Hitachi Software Engineering Co., Ltd., San Bruno, CA).

Figure 2 shows the amino acid sequence alignments among IPKC-2 (SEQ ID NO:1), rat putative protein kinase C inhibitor (GI 493055; SEQ ID NO:3), human PKCI-1 (GI 862933; SEQ ID NO:4), and bovine putative protein kinase C inhibitor (GI 493051; SEQ ID NO:5). The 5 alignment was produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figure 3 shows the hydrophobicity plot (MacDNASIS PRO software) for IPKC-2, SEQ ID NO: 1; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

10 Figure 4 shows the hydrophobicity plot for rat putative protein kinase C inhibitor, SEQ ID NO:3.

MODES FOR CARRYING OUT THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, 15 vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for 20 example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention 25 belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. 30 Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or

polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, "amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic molecules.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

10 "Peptide nucleic acid", as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

IPKC-2, as used herein, refers to the amino acid sequences of substantially purified IPKC-
15 2 obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin
20 Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte clone using the GELVIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both extended and assembled.

A "variant" of IPKC-2, as used herein, refers to an amino acid sequence that is altered by
25 one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted,
30 inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

A "deletion", as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

A "substitution", as used herein, refers to the replacement of one or more amino acids or 5 nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic IPKC-2, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or 10 cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which, when bound to IPKC-2, causes a change in IPKC-2 which modulates the activity of IPKC-2. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to IPKC-2.

The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when 15 bound to IPKC-2, blocks or modulates the biological or immunological activity of IPKC-2.

Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to IPKC-2.

The term "modulate", as used herein, refers to a change or an alteration in the biological activity of IPKC-2. Modulation may be an increase or a decrease in protein activity, a change in 20 binding characteristics, or any other change in the biological, functional or immunological properties of IPKC-2.

The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of IPKC-2 or portions thereof and, as such, is able to effect some or all of the actions of protein kinase C inhibitor-like molecules.

25 The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding IPKC-2 or the encoded IPKC-2. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

The term "substantially purified", as used herein, refers to nucleic or amino acid 30 sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

"Amplification" as used herein refers to the production of additional copies of a nucleic

acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term "hybridization", as used herein, refers to any process by which a strand of 5 nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences

10 hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed for in situ hybridization).

The terms "complementary" or "complementarity", as used herein, refer to the natural 15 binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, for the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has 20 significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence 25 is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for 30 and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The

absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

5 As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered
10 and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of
15 hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense
20 molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative"
25 is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein
30 "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length human IPKC-2 and fragments thereof.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various

methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells 5 include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a 10 protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

15 The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a 20 protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding IPKC-2 or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in 25 solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern 30 analysis is indicative of the presence of mRNA encoding IPKC-2 in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NO: 2, as used herein, comprise any alteration in the sequence of polynucleotides encoding IPKC-2 including deletions, insertions,

and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes IPKC-2 (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2), the inability of a selected fragment of SEQ ID NO: 2 to hybridize 5 to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding IPKC-2 (e.g., using fluorescent *in situ* hybridization [FISH] to metaphase chromosomes spreads).

As used herein, the term "antibody" refers to intact molecules as well as fragments 10 thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind IPKC-2 polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from the transition of RNA or synthesized chemically, and 15 can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

20 THE INVENTION

The invention is based on the discovery of a novel human protein kinase C inhibitor-like protein, (IPKC-2), the polynucleotides encoding IPKC-2, and the use of these compositions for the diagnosis, prevention, or treatment of cancer, autoimmune disorders, and cognitive disorders.

Nucleic acids encoding the human IPKC-2 of the present invention were first identified in 25 Incyte Clone 2366261 from the adrenal tissue cDNA library (ADREN0T07) through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 2366261 (ADREN0T07), 1755666 (LIVRTUT01), and 1852127 (LUNGFET03).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid 30 sequence of SEQ ID NO:1, as shown in Figures 1A and 1B. IPKC-2 is 118 amino acids in length and has chemical and structural homology with rat putative protein kinase C inhibitor (GI 493051; SEQ ID NO:3), human PKCI-1 (GI 862933; SEQ ID NO:4), and bovine putative protein kinase C inhibitor (GI 493050; SEQ ID NO:5; Figure 2). In particular, IPKC-2 shares 29%

identity with rat putative protein kinase C inhibitor. Especially noteworthy, is the greater than 66% identity in a putative zinc binding domain between amino acid residues 108 and 118 (Fig. 2). As illustrated by Figures 3 and 4, IPKC-2 and rat putative protein kinase C inhibitor have rather similar hydrophobicity plots. Northern analysis revealed the expression of this sequence in 5 various cDNA libraries, a high proportion of which are derived from cancer patients.

The invention also encompasses IPKC-2 variants. A preferred IPKC-2 variant is one having at least 80%, and more preferably 90%, amino acid sequence similarity to the IPKC-2 amino acid sequence (SEQ ID NO:1). A most preferred IPKC-2 variant is one having at least 95% amino acid sequence similarity to SEQ ID NO:1.

10 The invention also encompasses polynucleotides which encode IPKC-2. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of IPKC-2 can be used to generate recombinant molecules which express IPKC-2. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Figures 1A and 1B.

15 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding IPKC-2, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These 20 combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring IPKC-2, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode IPKC-2 and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring IPKC-2 under 25 appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding IPKC-2 or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence 30 encoding IPKC-2 and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or portions thereof,

which encode IPKC-2 and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding
5 IPKC-2 or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe, as taught in Wahl, G.M. and S.L.
10 Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511), and may be used at a defined stringency.

Altered nucleic acid sequences encoding IPKC-2 which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent IPKC-2. The encoded protein may also
15 contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent IPKC-2. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of IPKC-2 is retained. For example, negatively charged amino acids may include aspartic acid and glutamic
20 acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the genes encoding
25 IPKC-2. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
30 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such

enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp., Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD).

5 Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleic acid sequences encoding IPKC-2 may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream 10 sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the 15 same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may 20 be designed using OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

25 Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing 30 PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This

process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed 5 library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In 10 particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. GenotyperTM and Sequence NavigatorTM, Perkin Elmer) and the entire process from loading of samples to computer analysis. 15 and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode IPKC-2, or fusion proteins or functional equivalents thereof, may be used in 20 recombinant DNA molecules to direct expression of IPKC-2 in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express IPKC-2.

As will be understood by those of skill in the art, it may be advantageous to produce 25 IPKC-2-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

30 The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter IPKC-2 encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene

fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding IPKC-2 may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of IPKC-2 activity, it may be useful to encode a chimeric IPKC-2 protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the IPKC-2 encoding sequence and the heterologous protein sequence, so that IPKC-2 may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding IPKC-2 may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl.

Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232).

Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of IPKC-2, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of IPKC-2, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active IPKC-2, the nucleotide sequences encoding IPKC-2 or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding IPKC-2 and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described in

Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding IPKC-2. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding IPKC-2, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for IPKC-2. For example, when large quantities of IPKC-2 are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding IPKC-2 may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as

fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding IPKC-2 may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196).

An insect system may also be used to express IPKC-2. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding IPKC-2 may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of IPKC-2 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which IPKC-2 may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding IPKC-2 may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing IPKC-2 in infected host cells

(Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding IPKC-2. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding IPKC-2, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. 15 Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express IPKC-2 may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These

include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk^r or aprt^r cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which 5 confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinothricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or 10 hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific 15 vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding IPKC-2 is inserted within a marker gene sequence, recombinant cells containing sequences encoding IPKC-2 can be identified by the absence of marker gene function. 20 Alternatively, a marker gene can be placed in tandem with a sequence encoding IPKC-2 under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding IPKC-2 and express IPKC-2 may be identified by a variety of procedures known to those of skill in the art. 25 These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding IPKC-2 can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of 30 polynucleotides encoding IPKC-2. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding IPKC-2 to detect transformants containing DNA or RNA encoding IPKC-2. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60

nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplifier.

A variety of protocols for detecting and measuring the expression of IPKC-2, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples 5 include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on IPKC-2 is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St 10 Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding IPKC-2 include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled 15 nucleotide. Alternatively, the sequences encoding IPKC-2, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, 20 Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding IPKC-2 may be cultured 25 under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode IPKC-2 may be designed to contain signal sequences which direct secretion of IPKC-2 through a prokaryotic or eukaryotic cell membrane. 30 Other recombinant constructions may be used to join sequences encoding IPKC-2 to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A

domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and IPKC-2 may be used to facilitate purification.

5 One such expression vector provides for expression of a fusion protein containing IPKC-2 and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3:263-281) while the enterokinase cleavage site provides a means for purifying IPKC-2 from the fusion protein. A
10 discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of IPKC-2 may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation.
15 Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of IPKC-2 may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

Chemical and structural homology exists among IPKC-2, rat putative protein kinase C inhibitor, human PKCI-1, and bovine putative protein kinase C inhibitor. In addition, IPKC-2 is expressed in tissue derived from cancer patients. Therefore, IPKC-2 appears to be associated with the development of cancer, autoimmune disorders, and cognitive disorders.

20 PKC inhibitors have been shown to trigger apoptosis in a large number of cancer cell lines. In addition, inhibition of PKC activity in tumor cells may diminish MDR while maintaining sensitivity to chemotherapy. Therefore, in one embodiment, IPKC-2 or a fragment or derivative thereof may be administered to a subject to treat or prevent cancer. Types of cancer include, but are not limited to, cancers of the colon, liver, brain, small intestine, large intestine, breast, ovary, kidney, lung, and prostate.

25 In another embodiment, a vector capable of expressing IPKC-2, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent cancer including, but not limited, the types of cancers listed above.

PKC inhibitors may also induce apoptosis in certain non-cancer cells, such as T-lymphocytes. Therefore, in one embodiment, IPKC-2 or a fragment or derivative thereof may be

administered to a subject to treat or prevent an autoimmune disorder, such disorders include but are not limited to, rheumatoid arthritis, multiple sclerosis, scleroderma, Grave's disease, Sjogren's disease, Crohn's disease, diabetes, lupus, allergies, asthma, and myasthenia gravis.

In another embodiment, a vector capable of expressing IPKC-2, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent an autoimmune disorder including, but not limited, the disorders listed above.

The cellular distribution of PKC is important for memory storage in neuronal cells and IPKC-2 can regulate the activity of PKC. Therefore, in one embodiment, IPKC-2 or a fragment or derivative thereof may be administered to a subject to treat or prevent a cognitive disorder, including but not limited to, Alzheimer's disease, dementia, and learning disabilities.

In another embodiment, a vector capable of expressing IPKC-2, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent a cognitive disorder including, but not limited, the disorders listed above.

In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or vectors described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of IPKC-2 may be produced using methods which are generally known in the art. In particular, purified IPKC-2 may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind IPKC-2.

The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with IPKC-2 or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as

lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to IPKC-2 have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of IPKC-2 amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to IPKC-2 may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce IPKC-2-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for IPKC-2 may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively,

Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays 5 using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between IPKC-2 and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering IPKC-2 epitopes is preferred, but a competitive binding assay may also be employed (Maddox, *supra*).

10 In another embodiment of the invention, the polynucleotides encoding IPKC-2, or any fragment thereof, or antisense molecules, may be used for therapeutic purposes. In one aspect, antisense to the polynucleotide encoding IPKC-2 may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding IPKC-2. Thus, antisense molecules may 15 be used to modulate IPKC-2 activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding IPKC-2.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or 20 from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense molecules complementary to the polynucleotides of the gene encoding IPKC-2. These techniques are described both in Sambrook et al. (*supra*) and in Ausubel et al. (*supra*).

25 Genes encoding IPKC-2 can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes IPKC-2. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a 30 month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding IPKC-2.

i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding IPKC-2.

15 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The 20 suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical 25 synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding IPKC-2. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

30 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterate linkages within the backbone of the molecule. This concept is inherent in the production of

PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

- 5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.
- 10 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of 15 the therapeutic effects discussed above. Such pharmaceutical compositions may consist of IPKC-2, antibodies to IPKC-2, mimetics, agonists, antagonists, or inhibitors of IPKC-2. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The 20 compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, 25 intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found 30 in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral

administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active 5 compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums 10 including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, 15 polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. 20 Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in 25 aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles 30 include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, 5 dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized 10 powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of IPKC-2, such labeling would include amount, frequency, and method of administration.

15 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in 20 cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example 25 IPKC-2 or fragments thereof, antibodies of IPKC-2, agonists, antagonists or inhibitors of IPKC-2, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic 30 index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the

ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind IPKC-2 may be used for the diagnosis of conditions or diseases characterized by expression of IPKC-2, or in assays to monitor patients being treated with IPKC-2, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for IPKC-2 include methods which utilize the antibody and a label to detect IPKC-2 in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring IPKC-2 are known in the art and provide a basis for diagnosing altered or abnormal levels of IPKC-2 expression. Normal or standard values for IPKC-2 expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to IPKC-2 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of IPKC-2 expressed in subject, control and disease, samples from biopsied tissues are

compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding IPKC-2 may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide 5 sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of IPKC-2 may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of IPKC-2, and to monitor regulation of IPKC-2 levels during therapeutic intervention.

10 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding IPKC-2 or closely related molecules, may be used to identify nucleic acid sequences which encode IPKC-2. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the 15 stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding IPKC-2, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the IPKC-2 encoding sequences. The 20 hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring IPKC-2.

Means for producing specific hybridization probes for DNAs encoding IPKC-2 include the cloning of nucleic acid sequences encoding IPKC-2 or IPKC-2 derivatives into vectors for the 25 production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the 30 like.

Polynucleotide sequences encoding IPKC-2 may be used for the diagnosis of conditions or diseases which are associated with expression of IPKC-2. Examples of such conditions or diseases include, but are not limited to, cancer of the colon, liver, and prostate; and disorders of

the adrenal gland. The polynucleotide sequences encoding IPKC-2 may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pIN, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered IPKC-2 expression. Such qualitative or quantitative methods are well known in the art.

5 In a particular aspect, the nucleotide sequences encoding IPKC-2 may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding IPKC-2 may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated
10 and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding IPKC-2 in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic
15 treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of IPKC-2, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a
20 sequence, or a fragment thereof, which encodes IPKC-2, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease.

25 Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to
30 months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical

symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding IPKC-2 may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of IPKC-2 include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequences which encode IPKC-2 may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) Blood Rev. 7:127-134, and Trask, B.J. (1991) Trends Genet. 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 30 1994 Genome Issue of Science (265:1981f). Correlation between the location of the gene encoding IPKC-2 on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences

between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, IPKC-2, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between IPKC-2 and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to IPKC-2 large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with IPKC-2, or fragments thereof, and washed. Bound IPKC-2 is then detected by methods well known in the art. Purified IPKC-2 can also be coated directly onto plates for use in the aforementioned drug screening techniques.

Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding IPKC-2 specifically compete with a test compound for binding IPKC-2. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with IPKC-2.

In additional embodiments, the nucleotide sequences which encode IPKC-2 may be used in any molecular biology techniques that have yet to be developed, provided the new techniques

rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

5

INDUSTRIAL APPLICABILITY

I ADRENOT07 cDNA Library Construction

The ADRENOT07 cDNA library was constructed from microscopically normal adrenal tissues obtained from a 61-year old Caucasian female. Pathology indicated no significant abnormality of the right and left adrenals. Patient history included the diagnosis of unspecified disorder of adrenal glands, depressive disorder, benign hypertension, vocal cord paralysis, hemiplegia, subarachnoid hemorrhage, communicating hydrocephalus, and neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct. Prior surgery included total excision of the pituitary gland. Patient medications included Calderol®, calcium, hismal and Premarin®. Family history included malignant prostate neoplasm in the father and malignant colon neoplasm 15 in the mother.

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NY) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient 20 temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and DNase treated at 37°C. Extraction and precipitation were repeated. The mRNA was isolated with the Qiagen Oligotex kit (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SuperScript 25 Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013, Gibco/BRL, Gaithersburg, MD). The cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pINCY 1. The plasmid pINCY 1 was subsequently transformed into DH5a™ competent cells (Cat. #18258-012; Gibco/BRL).

30 II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173, QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol

was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, Gibco/BRL) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the 5 plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA 10 Sequencing Systems; and the reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

After the reading frame was determined, the nucleotide sequences of the Sequence Listing as well as the amino acid sequences deduced from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases, which contain 15 previously identified and annotated sequences, were searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul (1993) *supra*, Altschul (1990) *supra*).

BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful 20 in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms such as the one described in Smith et al. (1992, Protein Engineering 5:35-51), incorporated herein by reference, could have been used when dealing with primary sequence patterns and secondary structure gap penalties. The sequences disclosed in this application have lengths of at least 49 nucleotides, and no more 25 than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach, as detailed in Karlin et al. (*supra*) and incorporated herein by reference, searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} 30 for nucleotides and 10^{-14} for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam); and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases,

mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp) for homology. The relevant database for a particular match were reported as GI_{xxx}±p (where xxx is pri, rod, etc., and if present, p = peptide). The product score is calculated as follows: the % nucleotide or amino acid identity [between the query and reference sequences] in BLAST is multiplied by the % maximum possible BLAST score [based on the lengths of query and reference sequences] and then divided by 100. Where an Incyte Clone was homologous to several sequences, up to five matches were provided with their relevant scores. In an analogy to the hybridization procedures used in the laboratory, the electronic stringency for an exact match was set at 70, and the conservative lower limit for an exact match was set at approximately 40 (with 1-2% error due to uncalled bases).

10 IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., *supra*).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, *supra*) are 15 used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$20 \quad \frac{\text{sequence identity} \times \text{maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually 25 identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding IPKC-2 occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and 30 percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of IPKC-2-Encoding Polynucleotides

Nucleic acid sequence of Incyte clone 2366261 or SEQ ID NO:2 is used to design

oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence 5 "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer 10 dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing 15 the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

20	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
25	Step 7	Repeat step 4-6 for 15 additional cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat step 8-10 for 12 cycles
30	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in 35 extending the sequence. Bands thought to contain the largest products are selected and removed from the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc., Chatsworth, CA). After recovery of the DNA, Klenow enzyme is

used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is 5 incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured 10 in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units 15 of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

25 Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, 30 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). 35 The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin

column (Pharmacia & Upjohn). A portion containing 10^7 counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN[®]).

5 The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT ARTM film (Kodak, Rochester, NY) is exposed to the
10 blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Antisense Molecules

Antisense molecules or the complement of the IPKC-2-encoding sequence, or any part thereof, is used to inhibit in vivo or in vitro expression of naturally occurring IPKC-2. Although
15 use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of IPKC-2, as shown in Figures 1A and 1B, is used to inhibit expression of naturally occurring IPKC-2. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A and 1B and used either to inhibit transcription by
20 preventing promoter binding to the upstream nontranslated sequence or translation of an IPKC-2-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or 5' coding sequence of the polypeptide as shown in Fig. 1.

25 VIII Expression of IPKC-2

Expression of IPKC-2 is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express IPKC-2 in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β-galactosidase, followed by
30 sequence containing the amino-terminal Met, and the subsequent seven residues of β-galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods

produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of IPKC-2 into the bacterial growth media which can be used directly in the following assay for activity.

5 IX Demonstration of IPKC-2 Activity

IPKC-2 activity can be assayed by measuring PKC activity. PKC activity is found by measuring the transfer of radioactivity from [γ -³²P]-ATP to a protein substrate, such as histone type III, myelin basic protein, or EGF receptor peptide (Kennelly P.J. et al. (1991) J. Biol. Chem. 266: 15555-15558). The reaction conditions (addition of Ca^{+2} , phospholipid, phorbol ester, etc) are adjusted to the isoform of PKC used. IPKC-2 is added to the reaction mixture prior to the addition of substrate. The effect on PKC activity is measured at many dosages of IPKC-2 and compared to a sample lacking IPKC-2.

X Production of IPKC-2 Specific Antibodies

IPKC-2 that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring IPKC-2 Using Specific Antibodies

Naturally occurring or recombinant IPKC-2 is substantially purified by immunoaffinity chromatography using antibodies specific for IPKC-2. An immunoaffinity column is constructed by covalently coupling IPKC-2 antibody to an activated chromatographic resin, such as CnBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing IPKC-2 is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of IPKC-2 (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/IPKC-2 binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as 5 urea or thiocyanate ion), and IPKC-2 is collected.

XII Identification of Molecules Which Interact with IPKC-2

IPKC-2 or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled IPKC-2, washed and any wells with 10 labeled IPKC-2 complex are assayed. Data obtained using different concentrations of IPKC-2 are used to calculate values for the number, affinity, and association of IPKC-2 with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the 15 invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are 20 intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: INCYTE PHARMACEUTICALS, INC.

(ii) TITLE OF THE INVENTION: NOVEL PROTEIN KINASE C INHIBITOR-LIKE PROTEIN

(iii) NUMBER OF SEQUENCES: 5

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
- (B) STREET: 3174 Porter Drive
- (C) CITY: Palo Alto
- (D) STATE: CA
- (E) COUNTRY: USA
- (F) ZIP: 94304

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER: IBM Compatible
- (C) OPERATING SYSTEM: DOS
- (D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

- (A) PCT APPLICATION NUMBER: To Be Assigned
- (B) FILING DATE: Herewith
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/812,828
- (B) FILING DATE: 06-MAR-1997

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Billings, Lucy J.
- (B) REGISTRATION NUMBER: 36,749
- (C) REFERENCE/DOCKET NUMBER: PF-0230 PCT

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 650-855-0555
- (B) TELEFAX: 650-845-4166
- (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 118 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: ADREN0T07
- (B) CLONE: 2366261

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Gln Asp Pro Lys Met Gln Val Tyr Lys Asp Glu Gln Val Val Val
 1 5 10 15
 Ile Lys Asp Lys Tyr Pro Lys Ala Arg Tyr His Trp Leu Val Leu Pro
 20 25 30
 Trp Thr Ser Ile Ser Ser Leu Lys Ala Val Ala Arg Glu His Leu Glu
 35 40 45
 Leu Leu Lys His Met His Thr Val Gly Glu Lys Val Ile Val Asp Phe
 50 55 60
 Ala Gly Ser Ser Lys Leu Arg Phe Arg Leu Gly Tyr His Ala Ile Pro
 65 70 75 80
 Ser Met Ser His Val His Leu His Val Ile Ser Gln Asp Phe Asp Ser
 85 90 95
 Pro Cys Leu Lys Asn Lys His Trp Asn Ser Phe Asn Thr Glu Tyr
 100 105 110
 Phe Leu Glu Ser Gln Glu
 115

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: ADREN0T07
- (B) CLONE: 2366261

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAAAAGATGC ACCTATCAAA AAGGAATCCC	TGGGCCACTG GAGTCAGG	TTGAAGATT	60
CTATGCAGGA CCCCAAAATG CAGGTTTACA	AAGATGAGCA GGTGGTGGTG	ATAAAGGATA	120
AATACCCAAA GCCCCGTTAC CATTGGCTGG	TCTTACCGTG GACCTCCATT	TCCAGTCTGA	180
AGGCTGTGGC CAGGGAACAC CTTGAACCTCC	TTAACGCATAT GCACACTGTG	GGGGAAAAGG	240
TGATTGTAGA TTTTGCTGGG TCCAGCAAAC	TCCGCTTCCG ATTGGGCTAC	CACGCCATT	300
CGAGTATGAG CCATGTACAT CTTCATGTGA	TCAGCCAGGA TTTTGATTCT	CCTTGCTTA	360
AAAACAAAAA ACATTGGAAT TCTTCAATA	CAGAATACTT CCTAGAATCA	CAAGAGTAGC	420
TGGGATTGAG CTTTCTTCC TTGCCTGCAG	CTGTGATCGA GATGGTACAA	G	471

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 493051

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ala Asp Glu Ile Ala Lys Ala Gln Val Ala Arg Pro Gly Gly Asp
 1 5 10 15
 Thr Ile Phe Gly Lys Ile Ile Arg Lys Glu Ile Pro Ala Lys Ile Ile
 20 25 30
 Tyr Glu Asp Asp Gln Cys Leu Ala Phe His Asp Ile Ser Pro Gln Ala
 35 40 45

Pro	Thr	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	Tyr	Ile	Ser	Gln	Ile	Ser
50							55				60				
Ala	Ala	Glu	Asp	Asp	Asp	Glu	Ser	Leu	Leu	Gly	His	Leu	Met	Ile	Val
65							70			75				80	
Gly	Lys	Lys	Cys	Ala	Ala	Asp	Leu	Gly	Leu	Lys	Lys	Gly	Tyr	Arg	Met
							85			90			95		
Val	Val	Asn	Glu	Gly	Ser	Asp	Gly	Gly	Gln	Ser	Val	Tyr	His	Val	His
							100			105			110		
Leu	His	Val	Leu	Gly	Gly	Arg	Gln	Met	Asn	Trp	Pro	Pro	Gly		
							115			120			125		

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 862933

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Gln	Val	Ala	Arg	Pro	Gly	Gly	Asp
1				5				10			15				
Thr	Ile	Phe	Gly	Lys	Ile	Ile	Arg	Lys	Glu	Ile	Pro	Ala	Lys	Ile	Ile
				20				25			30				
Phe	Glu	Asp	Asp	Arg	Cys	Leu	Ala	Phe	His	Asp	Ile	Ser	Pro	Gln	Ala
				35				40			45				
Pro	Thr	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	His	Ile	Ser	Gln	Ile	Ser
				50				55			60				
Val	Ala	Glu	Asp	Asp	Asp	Glu	Ser	Leu	Leu	Gly	His	Leu	Met	Ile	Val
				65				70			75			80	
Gly	Lys	Lys	Cys	Ala	Ala	Asp	Leu	Gly	Leu	Asn	Lys	Gly	Tyr	Arg	Met
							85			90			95		
Val	Val	Asn	Glu	Gly	Ser	Asp	Gly	Gly	Gln	Ser	Val	Tyr	His	Val	His
							100			105			110		
Leu	His	Val	Leu	Gly	Gly	Arg	Gln	Met	His	Trp	Pro	Pro	Gly		
							115			120			125		

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 493050

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Gln	Val	Ala	Arg	Pro	Gly	Gly	Asp
1				5				10			15				
Thr	Ile	Phe	Gly	Lys	Ile	Ile	Arg	Lys	Glu	Ile	Pro	Ala	Lys	Ile	Ile
				20				25			30				

Tyr Glu Asp Asp Gln Cys Leu Ala Phe His Asp Ile Ser Pro Gln Ala
35 40 45
Pro Thr His Phe Leu Val Ile Pro Lys Lys Tyr Ile Ser Gln Ile Ser
50 55 60
Ala Ala Glu Asp Asp Asp Glu Ser Leu Leu Gly His Leu Met Ile Val
65 70 75 80
Gly Lys Lys Cys Ala Ala Asp Leu Gly Leu Lys Lys Gly Tyr Arg Met
85 90 95
Val Val Asn Glu Gly Ser Asp Gly Gly Gln Ser Val Tyr His Val His
100 105 110
Leu His Val Leu Gly Gly Arg Gln Met Asn Trp Pro Pro Gly
115 120 125

What is claimed is:

1. A substantially purified human protein kinase C inhibitor-like protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
2. An isolated and purified polynucleotide sequence encoding the human protein kinase C inhibitor-like protein of claim 1.
3. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.
4. A hybridization probe comprising the polynucleotide sequence of claim 2.
5. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.
6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 2 or variants thereof.
7. A hybridization probe comprising the polynucleotide sequence of claim 6.
8. An expression vector containing the polynucleotide sequence of claim 2.
9. A host cell containing the vector of claim 8.
10. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 the method comprising the steps of:
 - a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
11. A pharmaceutical composition comprising a substantially purified human protein kinase C inhibitor-like protein having an amino acid sequence of claim 1 in conjunction with a suitable pharmaceutical carrier.
12. A purified antibody which binds specifically to the polypeptide of claim 1.
13. A purified agonist which specifically modulates the activity of the polypeptide of claim 1.
14. A purified antagonist which specifically modulates the activity of the polypeptide of claim 1.
15. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 11.
16. A method for treating an autoimmune disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 11.

17. A method for treating a cognitive disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 11.

18. A method for detection of a polynucleotide which encodes human protein kinase C inhibitor-like protein in a biological sample comprising the steps of:

5 a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and

 b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human protein kinase C inhibitor-like protein in said biological sample.

1 / 5

AAA	GAT	GCA	CCT	ATC	AAA	AAG	GAA	TCC	CTG	GGC	CAC	TGG	AGT	CAA	GGC	GGC	TTG	AAG
11			20			29					38			47			56	
	65		74			83					92			101			110	
	ATT	TCT	ATG	CAG	GAC	CCC	AAA	ATG	CAG	GT ^T T	TAC	AAA	GAT	GAG	CAG	GTG	GTG	
M	Q	D	P	K	M	Q	V	K	Y	K	D	E	Q	V	V	V	V	
	119		128			137					146			155			164	
	ATA	AAG	GAT	AAA	TAC	CCA	AAG	GCC	CGT	TAC	CAT	TGG	CTG	GTC	TTA	CCG	TGG	ACC
I	K	D	K	Y	P	K	A	R	Y	H	W	L	V	L	P	W	T	
	173		182			191					200			209			218	
	TCC	ATT	TCC	AGT	CTG	AAG	GCT	GTG	GCC	AGG	GAA	CAC	CTT	GAA	CTC	CTT	AGG	CAT
S	I	S	S	L	K	A	V	A	R	E	H	L	E	L	L	K	H	
	227		236			245					254			263			272	
	ATG	CAC	ACT	GTG	GGG	GAA	AAG	GTG	ATT	GTA	GAT	TTT	GCT	GGG	TCC	AGC	AAA	CTC
M	H	T	V	G	E	K	V	I	V	D	F	A	G	S	S	K	L	
	281		290			299					308			317			326	
	CGC	TTC	CGA	TTG	GGC	TAC	CAC	GCC	ATT	CCG	AGT	ATG	AGC	CAT	GTA	CAT	CTT	CAT
R	F	R	L	G	Y	H	A	I	P	S	M	S	H	V	H	L	H	
	335		344			353					362			371			380	
	GTG	ATC	AGC	CAG	GAT	TTT	GAT	TCT	CCT	TGC	CTT	AAA	AAC	AAA	CAT	TGG	AAT	
V	I	S	O	D	F	D	S	P	C	L	K	N	K	H	W	N		

FIGURE 1A

2 / 5

	389	398	407	416	425	434											
TCT	TTC	AAT	ACA	GAA	TAC	TTC	CTA	GAA	TCA	CAA	GAG	TAG	CTG	GGA	TTT	GAC	TTT
S	F	N	T	E	Y	F	L	E	S	Q	E						
	443	452	461	470													
TCT	TCC	TTG	CCT	GCA	GCT	GTG	ATC	GAG	ATG	GTA	CAA	G					

FIGURE 1B

3/5

1 M Q D - - - - -
 1 M A D E I A K A Q V A R P G G D T I F G K I I R K E I P K M SEQ ID NO-1
 1 M A D E I A K A Q V A R P G G D T I F G K I I R K E I P A K GI 493051
 1 M A D E I A K A Q V A R P G G D T I F G K I I R K E I P A K GI 862933
 1 M A D E I A K A Q V A R P G G D T I F G K I I R K E I P A K GI 493050

7 Q V Y K D E Q V V V I K D K Y P K A R Y H W L V L P W T S I SEQ ID NO-1
 31 I I Y E D D Q C L A F H D I S P Q A P T H F L V I P K K Y I GI 493051
 31 I I F E D D R C L A F H D I S P Q A P T H F L V I P K K H I GI 862933
 31 I I Y E D D Q C L A F H D I S P Q A P T H F L V I P K K Y I GI 493050

37 S S L K A V A R E H L E L L K H M H T V G E K V I V D F A G SEQ ID NO-1
 61 S Q I S A A E D D D E S S L L G H L M I V G K C A A D L G L GI 493051
 61 S Q I S V A E D D D E S S L L G H L M I V G K C A A D L G L GI 862933
 61 S Q I S A A E D D D E S S L L G H L M I V G K C A A D L G L GI 493050

67 S S K L R F R I - - G Y H A I P S M S H V H L H V I S Q D F SEQ ID NO-1
 91 K K G Y R M V V N E G S D G G Q S V Y H V H L H V L G G - - GI 493051
 91 N K G Y R M V V N E G S D G G Q S V Y H V H L H V L G G - - GI 862933
 91 K K G Y R M V V N E G S D G G Q S V Y H V H L H V L G G - - GI 493050

95 D S P C L K N K K H W N S F N T E Y F L E S Q E SEQ ID NO-1
 119 - - - - - R Q M N W - - - - - P P G
 119 - - - - - R Q M H W - - - - - P P G
 119 - - - - - R Q M N W - - - - - P P G

FIGURE 2

4 / 5




FIGURE 3

5 / 5




FIGURE 4

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/04402

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C07K16/18 A61K38/17 C12N15/11
C12Q1/68 G01N33/50

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages.	Relevant to claim No.
X	EMBL database entry HSA53755; Accession number AA053755; 15. September 1996; Hillier et al.: 'The WashU-Merck EST project.' XP002071597 see abstract ---	3,5-7
X	EMBL database entry HS380226; Accession number H79380; 15. November 1995; Hillier et al.: 'The WashU-Merck EST project.' XP002071598 see abstract ---	3,5-7 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 July 1998

Date of mailing of the international search report

28.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/04402

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LIMA C. D. ET AL.: "THREE-DIMENSIONAL STRUCTURE OF HUMAN PROTEIN KINASE C INTERACTING PROTEIN 1, A MEMBER OF THE HIT FAMILY OF PROTEINS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, May 1996, pages 5357-5362, XP002043834 see the whole document ----	1-10, 18
A	BRZOSKA P. M. ET AL.: "CLONING, MAPPING, AND IN VIVO LOCALIZATION OF A HUMAN MEMBER OF THE PKCI-1 PROTEIN FAMILY (PRKCNH1)" GENOMICS, vol. 36, no. 1, 15 August 1996, pages 151-156, XP002043838 cited in the application see the whole document	1-11, 15, 18
A	WO 94 14798 A (GOEDECKE AG ; TROSTMANN UWE (DE); HARTENSTEIN JOHANNES (DE); BARTH) 7 July 1994 see abstract -----	15-17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/04402

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 15-18 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/04402

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9414798	A 07-07-1994	DE	4243321 A	23-06-1994
		AU	5813794 A	19-07-1994
		EP	0674632 A	04-10-1995
		JP	8504788 T	21-05-1996
		MX	9307983 A	31-08-1994
		US	5750555 A	12-05-1998